AstraZeneca Restarts MEK Inhibitor In Singapore Research Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Liver-cancer partnership includes failed melanoma drug.
You may also be interested in...
AstraZeneca/Array’s AZD6244 Fails Phase II For Melanoma
Firms enrolling patients for further trials of the drug candidate in ovarian cancer, hepatocellular and biliary tract carconomas.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.